Basic Information
Pregabalin Sandoz
Regulatory Information
EMEA/H/C/004010
June 19, 2015
April 23, 2015
21
November 22, 2024
Company Information
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication **Neuropathic pain** Pregabalin Sandoz is indicated for the treatment of peripheral and central neuropathic pain in adults. **Epilepsy** Pregabalin Sandoz is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. **Generalised Anxiety Disorder** Pregabalin Sandoz is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Pregabalin Sandoz. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Pregabalin Sandoz. For practical information about using Pregabalin Sandoz, patients should read the package leaflet or contact their doctor or pharmacist.